BNC 101

Drug Profile

BNC 101

Alternative Names: BNC-101; ET-101

Latest Information Update: 03 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biogen Idec
  • Developer Bionomics; Eclipse Therapeutics
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action G protein-coupled receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer
  • Preclinical Solid tumours
  • No development reported Cancer

Most Recent Events

  • 01 Mar 2016 Phase-I clinical trials in Colorectal cancer (Metastatic disease) in Australia (Parenteral) (NCT02726334)
  • 19 Oct 2015 Discontinued for Solid tumours in Australia (Parenteral)
  • 31 Aug 2015 The US FDA approves IND application for BNC 101 in Colorectal and pancreatic cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top